{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":40,"sponsored":0,"items":[{"id":"n_2f4wc2wqncu2xrfxfubq","seq":1484444,"kind":"article","title":"Fidson wins Roche-backed licence to make generic influenza drug for 129 countries","url":"https://businessday.ng/health/article/fidson-wins-roche-backed-licence-to-make-generic-influenza-drug-for-129-countries","summary":"Fidson Healthcare Plc, a Nigerian pharmaceutical manufacturer, has been selected by the Medicines Patent Pool (MPP) as one of 11 read more Fidson wins Roche-backed licence to make generic influenza drug for 129 countries","published":"2026-10-03T05:22:09Z","seen":"2026-10-03T06:02:19Z","lang":"en","country":"NG","source":{"id":"kite-businessday-ng-9308ed","name":"businessday.ng","domain":"businessday.ng","outlet":{"wikidata":"Q16733394","name":"Business Day","type":"newspaper","country":"NG","designations":["business newspaper","classified advertising","daily newspaper","organization"]}},"via":"kite-businessday-ng-9308ed","topics":["health","bdothernews"],"authors":["Royal Ibeh"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_2f4wc2wqncu2xrfxfubq","category":"economy-business","category_p":0.43,"category2":"health","sentiment":"positive","tone":0.38,"political":0.22},{"id":"n_2wc3mxpzhd5lgan23wia","seq":1462157,"kind":"article","title":"로슈 먹는 유방암약, CDK4/6 이후 진행위험 44%↓","title_en":"Breast cancer drug Roche, CDK4/6 after progression risk 44%↓","url":"https://www.medipana.com/news/articleView.html?idxno=418717","summary":"로슈의 차세대 경구용 유방암 치료 후보물질 \\'기레데스트란트(giredestrant)\\'가 CDK4/6 억제제 치료 이후 질환이 진행한 환자에서 기존 내분비요법보다 무진행생존기간(PFS)을 유의하게 연장했다. 특히 내분비요법 내성과 밀접한 ESR1 변이 환자에서는 질병 진행 또는 사망 위험을 62% 낮춘 것으로 나타났다. CDK4/6 억제제가 ER 양성 유방암의 주요 치료축으로 자리잡은 가운데 치료 이후 발생하는 내성을 어떻게 극복할지가 후속 치료제 개발의 새로운 경쟁 무대로 떠오르고 있다. 로슈는 지난 1일 ER 양성(ER+), HE","published":"2026-10-02T23:57:24Z","seen":"2026-10-03T02:01:34Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","파마시안"],"authors":["최봉선 기자"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_2wc3mxpzhd5lgan23wia","category":"health","category_p":0.78,"sentiment":"positive","tone":0.31,"political":0.1},{"id":"n_qw7yaegbx2coy77v2keq","seq":1290068,"kind":"article","title":"Börsen-Ticker: SMI mit kleiner Erholung - Neue Kursziele und Ratings für Schweizer Aktien - ABB und Amrize gefragt - Roche mit Verlusten - Fokus auf US-Arbeitsmarktdaten","title_en":"Stock market ticker: SMI with slight recovery - New price targets and ratings for Swiss stocks - ABB and Amrize in demand - Roche with losses - Focus on US labor market data","url":"https://www.cash.ch/news/top-news/borsen-ticker-smi-mit-kleiner-erholung-neue-kursziele-und-ratings-fur-schweizer-aktien-abb-und-amrize-gefragt-roche-mit-verlusten-fokus-auf-us-arbeitsmarktdaten-973587","summary":"+++Märkte+++ - Die Schweizer Börse notiert nach Handelsbeginn leicht höher.","published":"2026-10-02T05:39:00Z","seen":"2026-10-02T07:40:46Z","lang":"de","country":"CH","source":{"id":"kite-cash-ch-42f33f","name":"cash.ch","domain":"cash.ch","outlet":{"wikidata":"Q1047289","name":"Cash","type":"newspaper","country":"CH","designations":["business newspaper","online newspaper"]}},"via":"kite-cash-ch-42f33f","topics":["news"],"entities":[{"id":"Q1432699","name":"Samos International Airport","type":"other"},{"id":"Q30258448","name":"ABB","type":"org"},{"id":"Q135038266","name":"Amrize","type":"org"},{"id":"Q2160232","name":"Roche","type":"org"}],"image":"https://www.cash.ch/fp/1200/675/1280/959/sites/default/files/media/field_image/2025-09/amrize_transport_zement.jpg","story":"st_qw7yaegbx2coy77v2keq","category":"economy-business","category_p":0.88,"sentiment":"neutral","tone":0.08,"political":0.07},{"id":"n_vez7irvtnvdmctapycya","seq":1096365,"kind":"article","title":"로슈 HER2 양성 유방암 치료제 사회적 가치 8000억원…63%는 조기 치료서","title_en":"Roche HER2 positive breast cancer treatment has a social value of 800 billion won... 63% are in early treatment","url":"https://www.etoday.co.kr/news/view/2631615","summary":"국내 HER2 양성 유방암 환자에게 글로벌 제약사 로슈의 치료제를 사용하는 데 따른 사회적 가치가 2017년부터 2027년까지 약 ...","published":"2026-10-01T08:43:00Z","seen":"2026-10-01T09:14:46Z","lang":"ko","country":"KR","source":{"id":"kite-etoday-co-kr-278ce9","name":"etoday.co.kr","domain":"rss.etoday.co.kr"},"via":"kite-etoday-co-kr-278ce9","topics":["일반"],"authors":["노상우","author"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_plu3n33srxvwh7cbeo7q","category":"health","category_p":0.5,"category2":"economy-business","sentiment":"positive","tone":0.62,"political":0.08},{"id":"n_ld77jfwbj2wnlr54quxq","seq":1074060,"kind":"article","title":"Roche's Vabysmo Shows Real-World Effectiveness Across Retinal Diseases","url":"https://www.finanzen.ch/nachrichten/aktien/roches-vabysmo-shows-real-world-effectiveness-across-retinal-diseases-1036588323","published":"2026-10-01T07:12:45Z","seen":"2026-10-01T07:12:45Z","lang":"en","country":"CH","source":{"id":"finanzen.ch","name":"finanzen.ch","domain":"finanzen.ch"},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_2qi5vesxh4yaaavgzvjq","category":"health","category_p":0.72,"sentiment":"positive","tone":0.36,"political":0.02},{"id":"n_frg5dwdwc64ixvpiomcq","seq":1072556,"kind":"article","title":"Roche presents new data at EURETINA, highlighting Vabysmo's real-world effectiveness and safety across major retinal conditions","url":"https://www.manilatimes.net/2026/10/01/tmt-newswire/globenewswire/roche-presents-new-data-at-euretina-highlighting-vabysmos-real-world-effectiveness-and-safety-across-major-retinal-conditions/2436783","published":"2026-10-01T06:16:00Z","seen":"2026-10-01T07:12:01Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","health","education","science"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_2qi5vesxh4yaaavgzvjq","category":"health","category_p":0.54,"sentiment":"positive","tone":0.2,"political":0.07},{"id":"n_qrx2sayyue7lnxo5y23a","seq":1064625,"kind":"article","title":"F. Hoffmann-La Roche Ltd: Roche's giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine","url":"https://www.finanznachrichten.de/nachrichten-2026-10/69724812-f-hoffmann-la-roche-ltd-roche-s-giredestrant-combination-significantly-improved-progression-free-survival-in-er-positive-advanced-breast-cancer-in-p-399.htm","published":"2026-10-01T06:13:31Z","seen":"2026-10-01T06:13:31Z","lang":"en","country":"DE","source":{"id":"finanznachrichten.de","name":"finanznachrichten.de","domain":"finanznachrichten.de","outlet":{"wikidata":"Q1408247","name":"Finanznachrichten.de","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","business","science","health"],"authors":["GlobeNewswire (Europe)"],"entities":[{"id":"Q131882228","name":"F. Hoffmann-La Roche Ltd","type":"org"},{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q582728","name":"The New England Journal of Medicine","type":"org"}],"story":"st_xh67iaelhosqksymdknq","category":"health","category_p":0.73,"sentiment":"positive","tone":-0.13,"political":0.03},{"id":"n_2qi5vesxh4yaaavgzvjq","seq":1065275,"kind":"press_release","title":"Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditions","url":"https://www.globenewswire.com/news-release/2026/10/01/3372533/0/en/roche-presents-new-data-at-euretina-highlighting-vabysmo-s-real-world-effectiveness-and-safety-across-major-retinal-conditions.html","summary":"Basel, 1 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the VOYAGER study evaluating the effectiveness, durability and safety of Vabysmo® (faricimab) in neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). 1-3 Across all study cohorts, results confirm the real-world effectiveness of Vabysmo in line with Phase III trial results, with vision gains and robust…","published":"2026-10-01T06:00:00Z","seen":"2026-10-01T06:15:39Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","swx:ro","otc markets:rhhby","swx:rog","ch0012032113","us7711951043","ch0012032048","9014"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q140876515","name":"European Society of Retina Specialists","type":"org"}],"mentions":2,"story":"st_2qi5vesxh4yaaavgzvjq","category":"health","category_p":0.55,"sentiment":"positive","tone":0.39,"political":0.07},{"id":"n_qekrqqfpxnpdwwuzdr4a","seq":1063150,"kind":"article","title":"Roche publiziert ausführliche Giredestrant-Daten in Fachjournal","title_en":"Roche publishes detailed Giredestrant data in a medical journal","url":"https://www.cash.ch/news/top-news/roche-publiziert-ausfuhrliche-giredestrant-daten-in-fachjournal-973247","summary":"Pharma - Roche hat neue detaillierte Daten zu seinem Krebskandidaten Giredestrant veröffentlicht.","published":"2026-10-01T05:22:12Z","seen":"2026-10-01T06:04:29Z","lang":"de","country":"CH","source":{"id":"kite-cash-ch-42f33f","name":"cash.ch","domain":"cash.ch","outlet":{"wikidata":"Q1047289","name":"Cash","type":"newspaper","country":"CH","designations":["business newspaper","online newspaper"]}},"via":"kite-cash-ch-42f33f","topics":["news"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"image":"https://www.cash.ch/fp/1200/675/3360/2240/sites/default/files/media/field_image/2026-09/roche_pharma_basel.jpg","story":"st_qekrqqfpxnpdwwuzdr4a","category":"health","category_p":0.42,"category2":"science-technology","sentiment":"neutral","tone":0.08,"political":0.04},{"id":"n_xh67iaelhosqksymdknq","seq":1059158,"kind":"press_release","title":"Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine","url":"https://www.globenewswire.com/news-release/2026/10/01/3372515/0/en/roche-s-giredestrant-combination-significantly-improved-progression-free-survival-in-er-positive-advanced-breast-cancer-in-phase-iii-evera-data-published-in-the-new-england-journal.html","summary":"Basel, 1 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with everolimus significantly improved progression-free survival (PFS) versus standard endocrine therapy plus everolimus, were published in The New England Journal of Medicine (NEJM) . The evERA trial is evaluating giredestrant, an investigational oral selective oestrogen receptor degrader…","published":"2026-10-01T05:00:00Z","seen":"2026-10-01T05:24:16Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","swx:ro","otc markets:rhhby","swx:rog","ch0012032113","us7711951043","ch0012032048","9014"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q582728","name":"The New England Journal of Medicine","type":"org"}],"mentions":2,"story":"st_xh67iaelhosqksymdknq","category":"health","category_p":0.83,"sentiment":"positive","tone":0.62,"political":0.04},{"id":"n_cvxj53c4drbiyz2o7spa","seq":875152,"kind":"article","title":"Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program","url":"https://www.fiercebiotech.com/biotech/roche-zealand-see-phase-2-amylin-weight-loss-peak-mid-dose-start-pivotal-program","published":"2026-09-30T09:56:40Z","seen":"2026-09-30T09:56:40Z","lang":"en","source":{"id":"fiercebiotech.com","name":"fiercebiotech.com","domain":"fiercebiotech.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q705","name":"Zeeland","type":"org"}],"story":"st_cvxj53c4drbiyz2o7spa","category":"health","category_p":0.6,"category2":"economy-business","sentiment":"positive","tone":-0.19,"political":0.03},{"id":"n_i5x7jnoqwxlh4mf5zsoq","seq":861853,"kind":"article","title":"Roche Unveils Newborn Screening Test For 3 Genetic Conditions Of SMA, SCID, Sickle Cell Disease","url":"https://www.rttnews.com/3695085/roche-unveils-newborn-screening-test-for-3-genetic-conditions-of-sma-scid-sickle-cell-disease.aspx","published":"2026-09-30T06:20:00Z","seen":"2026-09-30T08:55:33Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q580290","name":"spinal muscular atrophy","type":"other"},{"id":"Q1334408","name":"severe combined immunodeficiency","type":"other"}],"story":"st_4mntj4konxce2a3aekkq","category":"health","category_p":0.76,"sentiment":"neutral","tone":-0.33,"political":0.04},{"id":"n_i6p2ytivft6hevqflida","seq":832175,"kind":"article","title":"Roche launches newborn screening test for three severe genetic conditions","url":"http://www.prnewswire.com/news-releases/roche-launches-newborn-screening-test-for-three-severe-genetic-conditions-302893267.html","published":"2026-09-30T05:40:22Z","seen":"2026-09-30T05:40:22Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["politics","economy","science","health"],"authors":["Roche"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_4mntj4konxce2a3aekkq","category":"health","category_p":0.74,"sentiment":"neutral","tone":-0.45,"political":0.1},{"id":"n_mvb63jwrrqz27d2yjmoa","seq":829241,"kind":"article","title":"F. Hoffmann-La Roche Ltd: Roche's fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis","url":"https://www.finanznachrichten.de/nachrichten-2026-09/69711776-f-hoffmann-la-roche-ltd-roche-s-fenebrutinib-is-the-first-btk-inhibitor-to-receive-u-s-fda-filing-acceptance-in-both-relapsing-and-primary-progress-399.htm","published":"2026-09-30T05:22:42Z","seen":"2026-09-30T05:22:42Z","lang":"en","country":"DE","source":{"id":"finanznachrichten.de","name":"finanznachrichten.de","domain":"finanznachrichten.de","outlet":{"wikidata":"Q1408247","name":"Finanznachrichten.de","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","politics","health","science"],"authors":["GlobeNewswire (Europe)"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q23304817","name":"fenebrutinib","type":"other"},{"id":"Q8277","name":"multiple sclerosis","type":"other"}],"story":"st_vh6kljddlfk7232w24zq","category":"health","category_p":0.58,"sentiment":"neutral","tone":-0.28,"political":0.1},{"id":"n_cx3jeqzei7hdkan4hpfq","seq":832203,"kind":"article","title":"Roche's fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis","url":"https://www.manilatimes.net/2026/09/30/tmt-newswire/globenewswire/roches-fenebrutinib-is-the-first-btk-inhibitor-to-receive-us-fdafiling-acceptance-in-both-relapsing-and-primary-progressive-multiple-sclerosis/2435722","published":"2026-09-30T05:12:00Z","seen":"2026-09-30T05:40:22Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","health","politics","science"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q23304817","name":"fenebrutinib","type":"other"},{"id":"Q423572","name":"Bruton's tyrosine kinase","type":"other"},{"id":"Q8277","name":"multiple sclerosis","type":"other"}],"story":"st_vh6kljddlfk7232w24zq","category":"health","category_p":0.6,"sentiment":"positive","tone":-0.17,"political":0.12},{"id":"n_vh6kljddlfk7232w24zq","seq":826959,"kind":"press_release","title":"Roche’s fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis","url":"https://www.globenewswire.com/news-release/2026/09/30/3371506/0/en/roche-s-fenebrutinib-is-the-first-btk-inhibitor-to-receive-u-s-fda-filing-acceptance-in-both-relapsing-and-primary-progressive-multiple-sclerosis.html","summary":"Basel, 30 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) under priority review for fenebrutinib, an investigational non-covalent Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The filing acceptance is based on data from the comprehensive…","published":"2026-09-30T05:00:00Z","seen":"2026-09-30T05:10:18Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business","swx:ro","otc markets:rhhby","swx:rog","ch0012032113","us7711951043","ch0012032048","9015"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q23304817","name":"fenebrutinib","type":"other"},{"id":"Q8277","name":"multiple sclerosis","type":"other"}],"mentions":2,"story":"st_vh6kljddlfk7232w24zq","category":"health","category_p":0.59,"sentiment":"positive","tone":0.28,"political":0.13},{"id":"n_ztnb326ettafvnkd443a","seq":846341,"kind":"article","title":"Börsen-Ticker: SMI startet positiv – Roche nach Meldung zu MS-Mittel gefragt – DocMorris baut Gewinne aus – Lindt&Sprüngli verlieren","title_en":"Stock Market Ticker: SMI starts positively – Roche in demand after MS drug announcement – DocMorris expands profits – Lindt&Sprüngli losses","url":"https://www.cash.ch/news/top-news/borsen-ticker-smi-startet-positiv-roche-nach-meldung-zu-ms-mittel-gefragt-docmorris-baut-gewinne-aus-lindtsprungli-verlieren-972648","summary":"+++MÄRKTE+++ - Die Schweizer Börse startet am Mittwoch freundlich in den Handel.","published":"2026-09-30T03:04:17Z","seen":"2026-09-30T07:35:32Z","lang":"de","country":"CH","source":{"id":"kite-cash-ch-42f33f","name":"cash.ch","domain":"cash.ch","outlet":{"wikidata":"Q1047289","name":"Cash","type":"newspaper","country":"CH","designations":["business newspaper","online newspaper"]}},"via":"kite-cash-ch-42f33f","topics":["news"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q669499","name":"DocMorris","type":"org"},{"id":"Q152822","name":"Lindt & Sprüngli","type":"org"}],"image":"https://www.cash.ch/fp/1200/675/1812/1209/sites/default/files/media/field_image/2025-01/thomas_schinecker_roche_pharma_0.jpg","story":"st_ztnb326ettafvnkd443a","category":"economy-business","category_p":0.86,"sentiment":"positive","tone":0.41,"political":0.02},{"id":"n_ghoqh7goy7aflof4owrq","seq":650676,"kind":"article","title":"Empresas.- Roche instala en el Centro Nacional de Análisis Genómico su primer equipo de secuenciación masiva en España","title_en":"Roche installs its first massive sequencing equipment in Spain at the National Center for Genomic Analysis","url":"https://www.infosalus.com/farmacia/noticia-empresas-roche-instala-centro-nacional-analisis-genomico-primer-equipo-secuenciacion-masiva-espana-20260929130243.html","summary":"La compañía Roche Diagnostics ha instalado en el Centro Nacional de Análisis Genómico (CNAG), ubicado en Barcelona, su primer secuenciador de ADN a gran escala, una tecnología que es capaz de analizar el genoma humano completo en solo cuatro horas, reduciendo el tiempo que requiere la secuenciación actual.","published":"2026-09-29T11:02:43Z","seen":"2026-09-29T11:15:46Z","lang":"es","source":{"id":"kite-infosalus-com-ae054a","name":"infosalus.com","domain":"infosalus.com"},"via":"kite-infosalus-com-ae054a","topics":["medicine","infosalus.com","farmacia"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"image":"https://img.europapress.es/fotoweb/fotonoticia_20260929130243_120.jpg","story":"st_ghoqh7goy7aflof4owrq","category":"economy-business","category_p":0.49,"category2":"science-technology","sentiment":"neutral","tone":0.32,"political":0.04},{"id":"n_7ldqy2we4irfsgyvkhba","seq":627717,"kind":"article","title":"Roche Bets On Data Generation And AI Independence To Strengthen Drug Development","url":"https://www.rttnews.com/3694545/roche-bets-on-data-generation-and-ai-independence-to-strengthen-drug-development.aspx","published":"2026-09-29T05:20:00Z","seen":"2026-09-29T09:25:18Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["business","economy","science"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_z6xba2nccfd6bc2s4odq","category":"science-technology","category_p":0.48,"category2":"economy-business","sentiment":"positive","tone":0.52,"political":0.07},{"id":"n_7bb7uf6qm4f6uqa54l2q","seq":569001,"kind":"article","title":"AI制药再迎巨头加码：罗氏布局自动化实验室 目标2..","title_en":"AI pharmaceutical manufacturing welcomes another giant investment: Roche plans automated laboratories, targeting 2...","url":"http://baijiahao.baidu.com/s?id=1877631866638322284","published":"2026-09-29T03:32:28Z","seen":"2026-09-29T03:32:28Z","lang":"zh","country":"CN","source":{"id":"kite-news-baidu-com-7bcc9f","name":"news.baidu.com","domain":"news.baidu.com"},"via":"kite-news-baidu-com-7bcc9f","entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_7bb7uf6qm4f6uqa54l2q","category":"science-technology","category_p":0.55,"category2":"economy-business","sentiment":"neutral","tone":0.19,"political":0.06},{"id":"n_5vusqffupz6wyrkh3lfa","seq":558785,"kind":"article","title":"로슈, 신약 연구에 '스스로 실험하는 AI 연구실' 도입","title_en":"Roche introduces'self-experimenting AI lab' for new drug research","url":"https://www.medipana.com/news/articleView.html?idxno=418381","summary":"로슈가 인공지능(AI)을 신약 후보 탐색과 실험 과정에 더 깊이 결합한다. 연구자가 AI의 분석 결과를 참고하는 데서 나아가, 실험과 데이터 분석을 반복하며 다음 연구 방향을 정하는 \\'자율형 연구실\\'을 구축하겠다는 구상이다. 로슈는 28일(현지시간) 영국 런덴에서 열린 투자자 행사 \\'파마 데이 2026\\'에서 이 같은 연구개발 전략을 소개했다. 발표를 맡은 아비브 레게브 제넨텍 초기 연구개발 책임자는 로슈가 AI를 활용한 자율형 연구실 구축을 최근 시작했다고 밝혔다. 로슈는 행사에서 실험과 분석 결과를 다음 연구에 반영하는 방식을 \\'","published":"2026-09-29T00:20:53Z","seen":"2026-09-29T01:50:20Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","파마시안"],"authors":["최봉선 기자"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_5vusqffupz6wyrkh3lfa","category":"science-technology","category_p":0.85,"sentiment":"neutral","tone":0.19,"political":0.07},{"id":"n_n7i5nbobmtrzw7erotba","seq":535580,"kind":"article","title":"Can Roche's Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?","url":"https://www.insidermonkey.com/news/can-roches-latest-obesity-drug-results-help-it-challenge-eli-lilly-and-novo-nordisk-1846125","published":"2026-09-28T22:39:17Z","seen":"2026-09-28T22:39:17Z","lang":"en","source":{"id":"insidermonkey.com","name":"insidermonkey.com","domain":"insidermonkey.com"},"via":"gdelt-gkg-english","topics":["business","economy","health"],"authors":["Noor Ul Ain Rehman"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q2984214","name":"Eli Lilly","type":"org"},{"id":"Q818846","name":"Novo","type":"org"}],"story":"st_n7i5nbobmtrzw7erotba","category":"health","category_p":0.49,"category2":"economy-business","sentiment":"neutral","tone":-0.01,"political":0.04},{"id":"n_hkltkntvrmatvpw53eoq","seq":509101,"kind":"article","title":"Roche drops obesity antibody after flunked interim analysis","url":"https://www.fiercebiotech.com/biotech/roche-drops-muscle-sparing-obesity-antibody-after-flunked-interim-analysis","published":"2026-09-28T19:37:15Z","seen":"2026-09-28T19:37:15Z","lang":"en","source":{"id":"fiercebiotech.com","name":"fiercebiotech.com","domain":"fiercebiotech.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_hkltkntvrmatvpw53eoq","category":"health","category_p":0.67,"sentiment":"neutral","tone":-0.35,"political":0.07},{"id":"n_wmfix52ijajaotakiu4q","seq":482820,"kind":"article","title":"Roche Plans Autonomous AI Labs To Accelerate Drug Discovery","url":"https://www.finanzen.ch/nachrichten/aktien/roche-plans-autonomous-ai-labs-to-accelerate-drug-discovery-1036578753","published":"2026-09-28T17:22:18Z","seen":"2026-09-28T17:22:18Z","lang":"en","country":"CH","source":{"id":"finanzen.ch","name":"finanzen.ch","domain":"finanzen.ch"},"via":"gdelt-gkg-english","topics":["economy","business"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_z6xba2nccfd6bc2s4odq","category":"science-technology","category_p":0.75,"sentiment":"neutral","tone":0.41,"political":0.08},{"id":"n_fcqhpgj6hl7r4kc4vola","seq":505240,"kind":"article","title":"Chugai Regains Emugrobart Rights After Roche Discontinuation, Stock Down","url":"https://www.rttnews.com/story.aspx?Id=3694420","published":"2026-09-28T15:50:00Z","seen":"2026-09-28T19:25:23Z","lang":"en","source":{"id":"rttnews.com","name":"rttnews.com","domain":"rttnews.com","outlet":{"wikidata":"Q60748698","name":"RTTNews","type":"news_agency","designations":["news agency","news website"]}},"via":"gdelt-gkg-english","topics":["business","economy","health"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_2xp2ttycdjt2o2w6hoaq","category":"economy-business","category_p":0.9,"sentiment":"neutral","tone":-0.11,"political":0.1},{"id":"n_yw7buy6z4tvf6ez7fy2a","seq":463581,"kind":"article","title":"Roche razvija laboratorije za razvoj novih lijekova kojima upravlja AI","title_en":"Roche develops laboratories for the development of new AI-managed drugs","url":"https://www.tportal.hr/biznis/clanak/roche-razvija-laboratorije-za-razvoj-novih-lijekova-kojima-upravlja-ai-20260928","summary":"Švicarski farmaceutski div Roche objavio je u ponedjeljak da planira uspostaviti laboratorije kojima upravlja umjetna inteligencija kako bi ubrzao istraživanje i razvoj novih lijekova","published":"2026-09-28T15:18:00Z","seen":"2026-09-28T15:30:20Z","lang":"hr","country":"HR","source":{"id":"kite-tportal-hr-37f260","name":"tportal.hr","domain":"tportal.hr","outlet":{"wikidata":"Q117744501","name":"Tportal.hr","type":"website","country":"HR","designations":["organization","serial","web portal"]}},"via":"kite-tportal-hr-37f260","topics":["biznis"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"image":"https://www.tportal.hr/media/thumbnail/500x300/2802857.jpeg?cropId=0","story":"st_z6xba2nccfd6bc2s4odq","category":"science-technology","category_p":0.84,"sentiment":"neutral","tone":0.19,"political":0.09},{"id":"n_ybbupxcixfs6iohihdna","seq":436404,"kind":"article","title":"AI at heart of Roche's future strategy","url":"https://www.swissinfo.ch/eng/pharma-health/ai-at-heart-of-roches-future-strategy/92132163","published":"2026-09-28T12:56:00Z","seen":"2026-09-28T13:24:28Z","lang":"en","country":"CH","source":{"id":"swissinfo.ch","name":"swissinfo.ch","domain":"swissinfo.ch","outlet":{"wikidata":"Q27479810","name":"Swissinfo, Dokumentation und Archive","type":"other","country":"CH","designations":["business archives","memory institution"]}},"via":"gdelt-gkg-english","topics":["economy","science","health"],"authors":["SWI swissinfo.ch"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_ybbupxcixfs6iohihdna","category":"science-technology","category_p":0.49,"category2":"economy-business","sentiment":"positive","tone":0.24,"political":0.07},{"id":"n_hcv43dxhenajppnglp7q","seq":428423,"kind":"article","title":"Roche setzt am Pharma Day auf Tempo","title_en":"Roche sets the pace at Pharma Day","url":"https://www.bluewin.ch/de/news/wirtschaft/roche-setzt-am-pharma-day-auf-tempo-li.3616508","summary":"Roche hat am sogenannten 'Pharma Day' eine klare Nachricht an den Markt: Der Konzern will weiterhin ganz vorne mitspielen.","published":"2026-09-28T11:58:35Z","seen":"2026-09-28T12:48:20Z","lang":"de","country":"CH","source":{"id":"kite-bluewin-ch-ae6e18","name":"bluewin.ch","domain":"bluewin.ch","outlet":{"wikidata":"Q886096","name":"Q886096","type":"other","designations":["business"]}},"via":"kite-bluewin-ch-ae6e18","entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_yjxlq75e5rm3jbd5sm6a","category":"economy-business","category_p":0.54,"category2":"health","sentiment":"positive","tone":0.5,"political":0.02},{"id":"n_35yz6h3mct434bhrowvq","seq":429363,"kind":"article","title":"Chugai Set to Reclaim Myostatin Drug Rights From Roche After Obesity Trial Falls Short","url":"https://tokyobrief.com/articles/chugai-emugrobart-gym329-obesity-halt-sma-restart","summary":"An interim analysis of Chugai's Phase 2 obesity trial for the myostatin antibody emugrobart found the targeted weight loss unlikely, so Roche is exiting the program entirely and is set to return all license rights to Chugai, which is now preparing, but has not decided, a possible return to spinal muscular atrophy development.","published":"2026-09-28T11:54:23Z","seen":"2026-09-28T12:52:19Z","lang":"ja","country":"JP","source":{"id":"kite-tokyobrief-com-a5667e","name":"tokyobrief.com","domain":"tokyobrief.com","outlet":{"wikidata":"Q141513445","name":"Tokyo Brief","type":"other","designations":["newsletter"]}},"via":"kite-tokyobrief-com-a5667e","entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"image":"https://tokyobrief.com/media/tokyo-brief-2026-09-28-chugai-emugrobart-gym329-obesity-halt-sma-restart-e520d5eacae3b80ec46976d6ad6c4db0159620333a3da335a3834d1ebed1b652.png?v=card","story":"st_35yz6h3mct434bhrowvq","category":"economy-business","category_p":0.48,"category2":"health","sentiment":"neutral","tone":-0.17,"political":0.24},{"id":"n_yjxlq75e5rm3jbd5sm6a","seq":428367,"kind":"article","title":"Roche setzt am Pharma Day auf Tempo - Wichtige Fragen und Antworten","title_en":"Roche focuses on speed at Pharma Day - Important questions and answers","url":"https://www.cash.ch/news/top-news/roche-setzt-am-pharma-day-auf-tempo-wichtige-fragen-und-antworten-972148","summary":"Ziele - Der Pharmakonzern Roche gibt sich ambitionierte Ziele vor.","published":"2026-09-28T11:47:13Z","seen":"2026-09-28T12:48:16Z","lang":"de","country":"CH","source":{"id":"kite-cash-ch-42f33f","name":"cash.ch","domain":"cash.ch","outlet":{"wikidata":"Q1047289","name":"Cash","type":"newspaper","country":"CH","designations":["business newspaper","online newspaper"]}},"via":"kite-cash-ch-42f33f","topics":["news"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"image":"https://www.cash.ch/fp/1200/675/2016/1154/sites/default/files/images/library/roche_pharma_basel_3.jpg","story":"st_yjxlq75e5rm3jbd5sm6a","category":"economy-business","category_p":0.46,"category2":"health","sentiment":"neutral","tone":0.13,"political":0.03},{"id":"n_z6xba2nccfd6bc2s4odq","seq":409381,"kind":"article","title":"Roche outlines plans to move towards autonomous AI labs","url":"https://www.channelnewsasia.com/business/roche-outlines-plans-move-towards-autonomous-ai-labs-6415631","published":"2026-09-28T11:05:48Z","seen":"2026-09-28T11:13:55Z","lang":"en","country":"SG","source":{"id":"cna","name":"CNA (Channel NewsAsia)","domain":"channelnewsasia.com","outlet":{"wikidata":"Q40238","name":"CNA","type":"other","country":"SG","designations":["news broadcasting","specialty channel"]}},"via":"cna","topics":["business"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"image":"https://dam.mediacorp.sg/image/upload/s--nO3hGRIv--/fl_relative,g_south_east,l_mediacorp:cna:watermark:2024-04:reuters_1,w_0.1/f_auto,q_auto/c_fill,g_auto,h_468,w_830/v1/one-cms/core/2026-09-28T110548Z_1_LYNXMPEM8R0TS_RTROPTP_3_ROCHE-RESULTS.JPG?itok=MC72lhtq","story":"st_z6xba2nccfd6bc2s4odq","category":"science-technology","category_p":0.85,"sentiment":"neutral","tone":0.17,"political":0.15},{"id":"n_mhfups5dim62wkclxa5a","seq":402254,"kind":"article","title":"Pharmakonzern: Roche trimmt Forschung auf Effizienz und peilt 20 neue Medikamente an","title_en":"Pharmaceutical company: Roche trims research for efficiency and aims for 20 new drugs","url":"https://www.handelsblatt.com/technik/medizin/pharmakonzern-roche-trimmt-forschung-auf-effizienz-und-peilt-20-neue-medikamente-an/100257931.html","summary":"Bis 2030 will Roche bis zu 20 neue Wirkstoffe auf den Markt bringen – mit einem Spitzenumsatzpotenzial von teilweise mehr als drei Milliarden Franken pro Wirkstoff.","published":"2026-09-28T10:16:17Z","seen":"2026-09-28T10:45:07Z","lang":"de","country":"DE","source":{"id":"kite-handelsblatt-com-3b4d32","name":"handelsblatt.com","domain":"handelsblatt.com","outlet":{"wikidata":"Q819697","name":"Handelsblatt","type":"newspaper","country":"DE","designations":["business newspaper","daily newspaper","news website","online newspaper"]}},"via":"kite-handelsblatt-com-3b4d32","topics":["medizin + gesundheit"],"authors":["Reuters"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"image":"https://images.handelsblatt.com/pnGgFA0xzkNa/cover/900/506/0/0/161/162/0.5/0.5/epa05266880-file-a-file-photo-dated-12-august-2005-showing-the-logo-of-swiss-drugmaker-roche-in-ba.jpg","story":"st_mhfups5dim62wkclxa5a","category":"economy-business","category_p":0.4,"category2":"health","sentiment":"neutral","tone":0.16,"political":0.1},{"id":"n_nytts5m3qu26nq6byf7q","seq":402577,"kind":"article","title":"Roche fait l'étal de son taux de succès en phase III","title_en":"Roche showcases its success rate in phase III","url":"https://www.bluewin.ch/fr/infos/economie/roche-fait-l-tal-de-son-taux-de-succ-s-en-phase-iii-li.3616362","summary":"Le géant des médicaments et du diagnostic Roche revendique en 2026 un taux de succès de 80% pour ses programmes cliniques avancés, contre 65% en 2025, à l'occasion de sa journée pour investisseurs lundi.","published":"2026-09-28T09:54:11Z","seen":"2026-09-28T10:46:55Z","lang":"fr","country":"CH","source":{"id":"kite-bluewin-ch-5267ac","name":"bluewin.ch","domain":"bluewin.ch","outlet":{"wikidata":"Q886096","name":"Q886096","type":"other","designations":["business"]}},"via":"kite-bluewin-ch-5267ac","entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_nytts5m3qu26nq6byf7q","category":"economy-business","category_p":0.66,"sentiment":"positive","tone":0.64,"political":0.05},{"id":"n_n2mg5562zisa5p5mbwoq","seq":383796,"kind":"press_release","title":"Global Cyclic Peptide Library Market Outlook and Forecast, 2026-2032 - AI-Enabled Discovery Fuels 16.32% CAGR Toward USD 9.86 Billion as PeptiDream, Bicycle Therapeutics, Pfizer and Roche Advance Competition","url":"https://www.globenewswire.com/news-release/2026/09/28/3369613/28124/en/global-cyclic-peptide-library-market-outlook-and-forecast-2026-2032-ai-enabled-discovery-fuels-16-32-cagr-toward-usd-9-86-billion-as-peptidream-bicycle-therapeutics-pfizer-and-roch.html","summary":"Boost ROI with question-led libraries, reproducible synthesis, validated assays, interoperable data, AI feedback loops, partnerships, and early planning for IP, regulation, supply and talent Boost ROI with question-led libraries, reproducible synthesis, validated assays, interoperable data, AI feedback loops, partnerships, and early planning for IP, regulation, supply and talent","published":"2026-09-28T09:07:00Z","seen":"2026-09-28T09:11:43Z","lang":"en","source":{"id":"globenewswire-all","name":"GlobeNewswire — all","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-all","topics":["business"],"entities":[{"id":"Q206921","name":"Pfizer","type":"org"},{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_n2mg5562zisa5p5mbwoq","category":"economy-business","category_p":0.47,"category2":"science-technology","sentiment":"positive","tone":0.51,"political":0.0},{"id":"n_njkxt6ocy2zkr6rusu5a","seq":379503,"kind":"article","title":"Roche-Tochter Chugai beendet die Entwicklung von Emugrobart bei Übergewicht","title_en":"Roche subsidiary Chugai ends development of Emugrobart for obesity","url":"https://www.cash.ch/news/top-news/roche-tochter-chugai-beendet-die-entwicklung-von-emugrobart-bei-ubergewicht-972045","summary":"Pharma - Die japanische Roche-Tochter Chugai stellt die klinische Entwicklung von Emugrobart ein.","published":"2026-09-28T07:44:14Z","seen":"2026-09-28T08:44:27Z","lang":"de","country":"CH","source":{"id":"kite-cash-ch-42f33f","name":"cash.ch","domain":"cash.ch","outlet":{"wikidata":"Q1047289","name":"Cash","type":"newspaper","country":"CH","designations":["business newspaper","online newspaper"]}},"via":"kite-cash-ch-42f33f","topics":["news"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"image":"https://www.cash.ch/fp/1200/675/1063/698/sites/default/files/media/field_image/2025-10/roche_analyse_biotech.jpeg","story":"st_njkxt6ocy2zkr6rusu5a","category":"health","category_p":0.54,"category2":"economy-business","sentiment":"negative","tone":-0.09,"political":0.05},{"id":"n_tjk3vge7wlzpvjoho7pq","seq":414883,"kind":"article","title":"Börsen-Ticker: US-Märkte vor dem Start tiefer - SMI knapp im Plus - Novartis überzeugt - Roche im Hintertreffen","title_en":"Stock Market Ticker: US markets lower before start - SMI barely in the plus - Novartis impresses - Roche lags behind","url":"https://www.cash.ch/news/top-news/borsen-ticker-us-markte-vor-dem-start-tiefer-smi-knapp-im-plus-novartis-uberzeugt-roche-im-hintertreffen-971972","summary":"+++Märkte+++ - Die Vorzeichen für den Handel an der Wall Street stehen schlecht.","published":"2026-09-28T04:20:00Z","seen":"2026-09-28T11:47:20Z","lang":"de","country":"CH","source":{"id":"kite-cash-ch-42f33f","name":"cash.ch","domain":"cash.ch","outlet":{"wikidata":"Q1047289","name":"Cash","type":"newspaper","country":"CH","designations":["business newspaper","online newspaper"]}},"via":"kite-cash-ch-42f33f","topics":["news"],"entities":[{"id":"Q507154","name":"Novartis","type":"org"},{"id":"Q2160232","name":"Roche","type":"org"}],"image":"https://www.cash.ch/fp/1200/675/2000/1331/sites/default/files/media/field_image/2023-08/wallstreet_wall_street_borse.jpg","story":"st_7fcr7v5zisztpkwcqpxa","category":"economy-business","category_p":0.85,"sentiment":"neutral","tone":-0.03,"political":0.04},{"id":"n_ifju3f5on45tbipfg6dq","seq":391634,"kind":"article","title":"Börsen-Ticker: SMI im Plus - Novartis stark - Roche fällt ins Minus - UBS weiter gefragt - Bitcoin fällt","title_en":"Stock market ticker: SMI in the plus - Novartis strong - Roche falls into the minus - UBS still in demand - Bitcoin falls","url":"https://www.cash.ch/news/top-news/borsen-ticker-smi-im-plus-novartis-stark-roche-fallt-ins-minus-ubs-weiter-gefragt-bitcoin-fallt-971972","summary":"+++Märkte+++ - Am Schweizer Aktienmarkt herrscht zum Wochenauftakt eine freundliche Stimmung.","published":"2026-09-28T04:20:00Z","seen":"2026-09-28T09:46:26Z","lang":"de","country":"CH","source":{"id":"kite-cash-ch-42f33f","name":"cash.ch","domain":"cash.ch","outlet":{"wikidata":"Q1047289","name":"Cash","type":"newspaper","country":"CH","designations":["business newspaper","online newspaper"]}},"via":"kite-cash-ch-42f33f","topics":["news"],"entities":[{"id":"Q1432699","name":"Samos International Airport","type":"org"},{"id":"Q507154","name":"Novartis","type":"org"},{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q193199","name":"UBS","type":"org"},{"id":"Q131723","name":"Bitcoin","type":"other"}],"image":"https://www.cash.ch/fp/1200/675/415/238/sites/default/files/images/library/six_zuerich_boerse_3.jpg","story":"st_7fcr7v5zisztpkwcqpxa","category":"economy-business","category_p":0.85,"sentiment":"neutral","tone":0.12,"political":0.05},{"id":"n_7fcr7v5zisztpkwcqpxa","seq":369132,"kind":"article","title":"Börsen-Ticker: SMI über 14'000 Punkte - Neue Kursziele und Rating - Roche und Novartis stark - ABB und Logitech im Rückwärtsgang","title_en":"Stock market ticker: SMI over 14,000 points - New price targets and ratings - Roche and Novartis strong - ABB and Logitech in reverse","url":"https://www.cash.ch/news/top-news/borsen-ticker-smi-uber-14000-punkte-neue-kursziele-und-rating-roche-und-novartis-stark-abb-und-logitech-im-ruckwartsgang-971972","summary":"+++Märkte+++ - Am Schweizer Aktienmarkt herrscht zum Wochenauftakt eine freundliche Stimmung.","published":"2026-09-28T04:20:00Z","seen":"2026-09-28T07:43:03Z","lang":"de","country":"CH","source":{"id":"kite-cash-ch-42f33f","name":"cash.ch","domain":"cash.ch","outlet":{"wikidata":"Q1047289","name":"Cash","type":"newspaper","country":"CH","designations":["business newspaper","online newspaper"]}},"via":"kite-cash-ch-42f33f","topics":["news"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q507154","name":"Novartis","type":"org"},{"id":"Q30258448","name":"ABB","type":"org"},{"id":"Q223127","name":"Logitech","type":"org"}],"image":"https://www.cash.ch/fp/1200/675/415/238/sites/default/files/images/library/six_zuerich_boerse_3.jpg","story":"st_7fcr7v5zisztpkwcqpxa","category":"economy-business","category_p":0.9,"sentiment":"neutral","tone":0.34,"political":0.06},{"id":"n_7dos5gdick77naygvgdq","seq":328680,"kind":"article","title":"로슈 CVRM 질환 신약 발굴 제휴","title_en":"Roche partners to discover new drugs for CVRM diseases","url":"https://www.bosa.co.kr/news/articleView.html?idxno=3012869","summary":"[의학신문·일간보사=김자연 기자] 로슈가 심혈관·신장·대사(CVRM) 질환의 여러 타깃에 대해 저분자 신약 발굴 제휴를 아타비스틱 바이오와 체결했다.아타비스틱은 대사-단백질 스크리닝 플랫폼 및 알로스테리 치료제 발굴 전문성으로 선택적 타깃에 대한 신규 기능 결합 포켓을 발견해 주기로 합의했다고 발표했다.기존 치료제는 질환-유발 단백질의 주요 활성 부위와 결합하는데 비해 새로운 접근을 통해 단백질 활성을 조절하는 부위에 숨겨진 포켓을 발견하며 더욱 선택적이고 비의도적 영향이 적은 치료제가 가능하다는 설명이다. 이에 아타비스틱은 발굴","published":"2026-09-28T02:27:25Z","seen":"2026-09-28T02:37:54Z","lang":"ko","source":{"id":"kite-bosa-co-kr-134b8e","name":"bosa.co.kr","domain":"bosa.co.kr","outlet":{"wikidata":"Q20445876","name":"Q20445876","type":"newspaper","country":"KR","designations":["newspaper"]}},"via":"kite-bosa-co-kr-134b8e","topics":["medicine","해외"],"authors":["김자연 기자"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_7dos5gdick77naygvgdq","category":"health","category_p":0.45,"category2":"economy-business","sentiment":"neutral","tone":0.18,"political":0.08},{"id":"n_t3hehopus7ur2r6y3fqa","seq":328689,"kind":"article","title":"로슈, 중 AI 이중특이 항암 항체 발굴 제휴","title_en":"Roche partners to discover dual-specificity anti-cancer antibodies in China","url":"https://www.bosa.co.kr/news/articleView.html?idxno=3012855","summary":"[의학신문·일간보사=김자연 기자] 로슈가 이어렌딜 랩스(Earendil Labs)와 AI로 이중 특이 항암 항체를 발굴하기로 제휴를 체결했다. 중국 이어렌딜은 로슈의 지넨텍과 합의한 타깃 조합에 대해 이같이 계약했다고 발표했다.이에 이어렌딜은 선금 5500만달러에 발굴 및 초기 임상개발까지 담당하고 지넨텍은 세계 임상 개발 및 판매를 맡으며 향후 개발·승인·판매 마일스톤으로 최대 14억4500만달러까지 지급할 수 있다.이어렌딜은 AI로 예측적 단백질 모델링에서 부터 생성형 디자인 및 신속 실험 검증에 이르기까지 생물약 R&D 작업흐","published":"2026-09-28T02:10:49Z","seen":"2026-09-28T02:37:54Z","lang":"ko","source":{"id":"kite-bosa-co-kr-134b8e","name":"bosa.co.kr","domain":"bosa.co.kr","outlet":{"wikidata":"Q20445876","name":"Q20445876","type":"newspaper","country":"KR","designations":["newspaper"]}},"via":"kite-bosa-co-kr-134b8e","topics":["medicine","해외"],"authors":["김자연 기자"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q29520","name":"China","type":"place"}],"story":"st_t3hehopus7ur2r6y3fqa","category":"science-technology","category_p":0.71,"sentiment":"neutral","tone":0.34,"political":0.11}]}